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Lowering low-density lipoprotein cholesterol (LDL-C) levels by statins
reduces cardiovascular events after acute coronary syndrome (ACS)
[1–3]. In addition, the Myocardial Ischemia Reduction with Aggressive
Cholesterol Lowering (MIRACL) Studydemonstrated that early treatment
with atorvastatin initiated 24–96 h after ACS reduced recurrent ischemic
events [4]. Thus, early initiation of treatment with statins after ACS is
commonly accepted in clinical practice. Although aggressive treatment
with statins enables attainment of targeted LDL-C levels, cardiovascular
events after ACS is still prevalent [5,6]. Among putative clinical therapies
guarding against residual cardiovascular risks, an increased intake of
omega-3 polyunsaturated fatty acids (PUFAs) including eicosapentaenoic
acid (EPA) and docosahexaenoic acid (DHA) has been reported to protect
against mortality after acute myocardial infarction (MI) [7–9].
Ingestion of omega-3 PUFAs including EPA and DHA may attenuate
the inﬂammatory response after MI through multiple mechanisms.
Omega-3 PUFAs are readily incorporated into lipid membranes and
modify cellular signaling, leading to the disruption of lipid raft–related
pro-inﬂammatory signaling [10]. In addition, the conversion of
omega-3 PUFAs into oxygenated bioactive derivatives such as resolvins
and protectins promotes the resolution of inﬂammation [11–14]. Recent
preclinical data have indicated that an acute inﬂammatory response
after MI accelerates systemic atherosclerosis [15–17]. These results sug-
gest that omega-3 PUFAs could reduce the intensity of the inﬂammatory
response, which then inﬂuences clinical outcome after ACS.
We have reported that early initiation of EPA treatment in patients
with acute MI reduced the inﬂammatory response as assayed by high-
sensitivity C-reactive protein (CRP) on days 3 and 4 [18]. However,
the impact of early EPA treatment after ACS on remote-stage clinical
outcomes remains unknown. The aim of this study was to investigate
whether early initiation of EPA treatment combined with a statin
started within 24 h after successful primary percutaneous coronary in-
tervention (PCI) reduced cardiovascular events compared with statin
monotherapy in patients after ACS.
2. Methods
2.1. Study design
This study consisted of a prospective, single-center randomized
open-labeled trial (Fig. 1). The study protocol was approved by the
ethics committee of Kagawa Prefectural Central Hospital, and written
informed consent was obtained from all patients.
2.2. Study population
Between November 2010 andMarch 2014, 329 consecutive ACS pa-
tients treated with PCI were eligible to participate as part of the studyFig. 1. Studypopulation (Fig. 2). ACS was diagnosed according to the American Col-
lege of Cardiology/American Heart Association 2007 guideline; recent-
onset chest pain, associated with ST segment and/or negative T wave
electrocardiogram (ECG) changes and/or positive cardiac enzymes (cre-
atine kinase or troponin T) [19]. Key exclusion criteria were cardiogenic
shock, severe renal insufﬁciency requiring dialysis, cardiopulmonary ar-
rest, emergent coronary artery bypass, failure of PCI, and expected prog-
nosis less than 1 year because of cancer. Among ACS patients who
enrolled in this study, 115 patients with acute myocardial patients
were overlapped with our previous study, which evaluated composite
events, including cardiac death, stroke, re-infarction, ventricular ar-
rhythmias, and paroxysmal atrial ﬁbrillation within 1 month after PCI.
[18]
2.3. Acute-stage treatment and study protocol
Before PCI, patients received 200mg aspirin and 300mg clopidogrel.
PCI was performed with conventional techniques by the femoral or ra-
dial approach. Intravenous heparin (10,000 IU) was administered after
arterial access was obtained to achieve an activated clotting time of
N200 s. Intravenous heparin was continued for 48 h after angioplasty,
followed by stent deployment. Post-procedural antithrombotic therapy
consisted of 100 mg aspirin daily and 75 mg clopidogrel daily. No pa-
tients received glycoprotein inhibitors during the study period.
After PCI, the patients were randomly assigned at a 1:1 ratio to two
groups: patients in one group received pitavastatin at a dose of 2 mg
plus EPA, which is highly (N98%) puriﬁed EPA ethyl ester (ethyl all-
cis-5,8,11,14,17-icosapentaenoate), at a dose of 1800 mg (EPA group);
those in the other received pitavastatin alone at a dose of 2 mg (control
group). Group placement was determined by a research technician ac-
cording to a computer-generated randomization plan that included
stratiﬁcation by gender and acute MI or unstable angina pectoris.
Drugs were started within 24 h after PCI and were continued for at
least 52 weeks. We checked the condition of each patient at 1, 3, 6, 9,
and 12 months after the initiation of therapy. Laboratory examinations
were performed for each patient at admission and 6–9 months after
the initiation of therapy.
2.4. End points
The primary composite end point consisted of death from a cardio-
vascular cause, or nonfatal MI, nonfatal stroke, coronary revasculariza-
tion for new lesions with either PCI or coronary artery bypass graft
(CABG).We assessed the ﬁrst occurrence of one of these events starting
from the time of randomization. The secondary composite end point
consisted of either a primary end point or hospitalization for heart fail-
ure after starting study drugs. Non-fatal acute MI was deﬁned as having
at least two of the following: chest pain of typical intensity and dura-
tion; ST segment elevation or depression of ≥1 mm in any limb lead ofprotocol.
Fig. 2. Flow diagram of this study. MI, myocardial infarction; CAG, coronary angiography; PCI, percutaneous coronary intervention; EPA, eicosapentaenoic acid.
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of necrosis enzyme levels. Diagnosis of non-fatal stroke required un-
equivocal signs or symptoms of remaining neurological deﬁcit, with
sudden onset and a duration of N24 h.
2.5. Data collection
Serum lipids—total cholesterol, HDL-cholesterol (HDL-C), and
triglyceride—were measured using an autoanalyzer and routine
methods. LDL-C levels were calculated using Friedewald's equation.
Concentrations of EPA and DHA were measured on admission (quanti-
ﬁcation by SRL Company, Tokyo, Japan). Data regarding primary and
secondary outcomes were collected from clinical charts, and diagnoses
were conﬁrmed by an investigator (M.I.), who was blind to treatment
allocation.
2.6. Statistical analysis
We assumed that the prevalence of the primary outcomes would be
reduced from 15% to 5% by EPA treatment. Regarding incidence of the
primary outcomes, the MIRACL study has reported that the incidence
of primary outcomes including deﬁned as death, nonfatal acutemyocar-
dial infarction, cardiac arrest with resuscitation, or recurrent symptom-
atic myocardial ischemia with objective evidence and requiring
emergency rehospitalization was 15% in the in the atorvastatin group.
In addition, regarding the reduction of outcomes with EPA treatment,
our previous study showed that early EPA treatment after PCI in acute
myocardial infarction (AMI) patients reduced cardiac death, stroke, re-
infarction, ventricular arrhythmias, and paroxysmal atrial ﬁbrillation
within 1 month from 29% to 11%; therefore, to ensure statistical signiﬁ-
cance in the detection of reduction within this range (power 80%, α=
0.05), 322 patients were recruited into the study. Sample size was
based on anticipated event rates at 1 year of 15% in the control arm
[20]. Our previous study showed that early EPA treatment after PCI in
AMI patients reduced composite events by one-third [18]. All data
were tested for the normal distribution with the Kolmogorov–
Smirnov test. Data that conformed to a normal distribution are summa-
rized as themean± standard deviation; those that did not are shown asthe median and the ﬁrst and third quartile. Continuous variables were
compared using a paired or unpaired Student's t-test or Mann–
Whitney U-test, as appropriate. Estimates of the hazard ratios (HRs)
and associated 95% conﬁdence intervals (CIs) in comparing control
and EPA groups were obtained with the use of the Cox proportional-
hazards model. Changes in lipid parameters between the two groups
were compared using a repeated analysis of variance (ANOVA). A p-
value of b0.05 was considered statistically signiﬁcant. Statistical analy-
sis was performed using SPSS 17.0 forWindows (SPSS Inc., Chicago, IL).
3. Results
3.1. Study population
Fig. 2 shows the trial proﬁle. From the initial 329 patients with ACS,
57 patients were excluded. From the remaining 272 patients undergo-
ing emergent PCI, 29 patients refused consent and 2 had failed PCI. Of
the 241 patients who were enrolled and randomly assigned to the EPA
and control groups (120 and 121, respectively), 1 patient from the
EPA group was excluded because of drug eruption, and 2 patients
from the control group were excluded because they did not return for
a follow-up, leaving a total of 119 patients in each group. Table 1
shows the baseline characteristics for the patients and the coronary
anatomy and angiographic results of the two groups, which were com-
parable in age, gender, prevalence of diabetes, hypertension, dyslipid-
emia, and acute MI. In those patients with acute MI (control, n = 77;
EPA, n=80), the two groupswere also comparable in Killip class on ad-
mission, culprit vessel, onset-to-reperfusion, and ﬁnal thrombolysis in
MI (TIMI) ﬂow grade.
At the time of randomization, there was no signiﬁcant difference in
the ratio of EPA to arachidonic acid (AA) or the lipid proﬁle before PCI
(Table 1). The reduction in LDL-C was comparable between the two
groups (p= 0.21 by repeated ANOVA), and the ﬁnal mean LDL-C levels
were 120.8 mg/dl and 117.7 mg/dl in the control and EPA groups, re-
spectively (Fig. 3). Triglyceride did not change during the study period
and remained comparable between the two groups (p = 0.61). Final
mean triglyceride levels were 138.8 mg/dl and 120.8 mg/dl in the con-
trol and EPA groups, respectively. The plasma EPA concentration in
Table 1
Baseline characteristics of patients.
Control (n = 119) EPA (n = 119) p
Age, years 71 ± 12a 70 ± 11 0.33
Males 90 (76) 92 (77) 0.72
Body mass index, kg/m2 24.0 ± 3.6 23.8 ± 3.9 0.68
Diabetes mellitus 41 (34) 51 (43) 0.18
Hypertension 82 (69) 85 (71) 0.68
Dyslipidemia 77 (65) 84 (71) 0.33
Current smoking 38 (32) 33 (28) 0.48
Prior MI 7 (6) 14 (12) 0.11
Prior PCI 15 (13) 20 (17) 0.36
Prior CABG 2 (2) 4 (3) 0.68
History of stroke 15 (13) 8 (7) 0.12
Index event
MI without ST-segment elevation 14 (12) 13 (11) 0.84
MI with ST-segment elevation 63 (53) 67 (56) 0.79
Unstable angina 42 (35) 39 (33) 0.68
Lipid values
Total cholesterol, mg/dl 182 ± 41 185 ± 35 0.6
LDL-C, mg/dl 116 (98–134) 118 (98–132) 0.56
HDL-C, mg/dl 43 ± 11 43 ± 11 0.86
Triglycerides, mg/dl 105 (51–123) 117 (52–122) 0.59
Fatty acids
EPA, μg/ml 65 (37–84) 63 (37–81) 0.85
AA, μg/ml 174 ± 50 170 ± 43 0.57
EPA/AA 0.39 (0.21–0.51) 0.38 (0.24–0.45) 0.96
Medications at discharge
Aspirin 119 (100) 119 (100) 1.0
Ticlopidine 113 (95) 116 (97) 0.31
ARB/ACE-I 58 (49) 61 (51) 0.7
β-blockers 70 (60) 68 (58) 0.79
Statins 119 (100) 119 (100) 1.0
MI with or without ST-segment
elevation
Control
(n = 77)
EPA (n = 80) p
Onset-to-reperfusion time, h 5.8 (2.6–7.8) 6.0 (2.5–7.5) 0.96
Infarct-related artery (LAD/non-LAD) 32/45 35/45 0.78
Killip class (1/2/3) 43/24/10 45/30/5 0.31
TIMI ﬂow grade on admission (0/1 or
2/3)
50/21/6 52/26/2 0.28
TIMI ﬂow grade after PCI (2/3) 14/63 12/68 0.59
Peak creatine kinase, IU/l 2097
(1032–3228)
2104
(1243–3561)
0.49
Abbreviations: AA, arachidonic acid; ARB, angiotensin II receptor blocker; ACE-I, angioten-
sin conversion enzyme inhibitor; CABG, coronary artery bypass graft; EPA,
eicosapentaenoic acid; LAD, left anterior descending artery; MI, myocardial infarction;
PCI, percutaneous coronary intervention; TIMI, thrombolysis in myocardial infarction.
a Values are expressed as the mean ± SD, as the median (twenty-ﬁfth percentile to
seventy-ﬁfth percentile), or as the number of patients followed by the percentage (in
parentheses).
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control group (65.5 μg/ml) during follow-up (p b 0.001). Similarly, the
EPA/AA ratio of the EPA group increased more than that of the control
group, and this difference was maintained during follow-up (ﬁnal ra-
tios, 1.15 vs. 0.39, respectively; p b 0.001).3.2. Primary and secondary outcomes
Kaplan–Meier event rates for the primary end point of cardiovascu-
lar death,MI, stroke, or coronary revascularization at 1 yearwere 9.2% in
the EPA group and 20.2% in the control group (absolute risk reduction,
11.0%; HR, 0.42; 95% CI, 0.21–087; P = 0.02) (Fig. 4A, Table 2). In
terms of non-cardiovascular death, 4 patients in the control group
died due to pneumonia, (n=3) and trafﬁc accident (n=1) and onepa-
tients in the EPA group died due to pneumonia (n= 1). The rate of the
secondary end point of cardiovascular death,MI, stroke, coronary revas-
cularization, or hospitalization for heart failure was signiﬁcantly lower,
by 10.9%, in the EPA group than in the control group (HR, 0.90; 95% CI,
0.26–0.98; p=0.04) (Fig. 4B and Table 2). Notably, death from a cardio-
vascular cause at 1 yearwas signiﬁcantly lower in the EPA group than inthe control group (4.2% vs. 0.8%; absolute risk reduction, 5.9%; HR, 0.22;
95% CI, 0.47–0.99; p = 0.04) (Table 2).
4. Discussion
After ACS, early initiation of a combined EPA and statin treatment
within 24 h after successful primary PCI resulted in a signiﬁcantly
lower risk of cardiovascular events than that obtained with statin
monotherapy. The reduction of primary outcomes was mainly due to
a decrease in death from a cardiovascular cause. This is the ﬁrst study
to assess the additive effect of 1800mg/day of EPA treatment combined
with a statin on cardiovascular events after ACS comparedwith the out-
come from therapy with a statin alone.
Our study is different from those reported previously in several as-
pects. First, EPA treatment was started within 24 h after primary PCI.
Previous randomized clinical trials reported the usefulness of omega-3
PUFAs for the prevention of secondary adverse cardiovascular events
in post-MI patients. Results from the Gruppo Italiano per lo Studio
della Streptochinasi nell'Infarto Miocardico (GISSI) prevention trial
have shown that treatmentwith EPA+DHA (1 g/day) lowered sudden
cardiac death in patients after MI [7]. In the GISSI prevention trial,
omega-3 PUFA was started within 3 months after MI. In the Japan EPA
Lipid Intervention Study (JELIS), hypercholesterolemic patients with
or without a history of cardiovascular events were administered EPA
(1.8 g/day) in combination with a mild statin; the results showed a re-
duction in cardiovascular events for all participants [20]. In our study,
EPA treatmentwas initiatedwithin 24 h after primary PCI, which is ear-
lier than in the MIRACL Study that reported the beneﬁts of early treat-
ment with atorvastatin initiated 24–96 h after ACS [4]. In our pilot
randomized study, the EPA/AA ratio was increased 1 day after intake
of EPA (1800 mg/day) and was signiﬁcantly higher on the third day in
EPA-treated subjects as compared with levels in control subjects
(p b 0.05, data not shown). Thus, the early initiation of EPA treatment
increased plasma EPA concentration within a few days. Second, all pa-
tients included in this study underwent primary PCI successfully. In
the GISSI prevention trial, patients treated by thrombolysis were in-
cluded. Third, pitavastatin was administered to all patients regardless
of EPA treatment. A substudy of JELIS showed EPA is effective for pre-
vention of secondary coronary artery disease, especially in individuals
with prior MI [21]. However, in JELIS, a mild statin was administered
with EPA treatment. Taken together, these differences strengthen our
ﬁnding that early initiation of EPA treatment is beneﬁcial in patients un-
dergoing primary PCI and receiving a statin after ACS.
There are several possiblemechanisms for the observed relationship
between EPA treatment and the reduction of cardiovascular events after
ACS. Ventricular arrhythmia after primary PCI in patients with acute MI
is reported to be associatedwith an increased 90-daymortality [22].We
have reported that early EPA treatment after primary PCI reduced the
incidence of ventricular arrhythmias in the acute stage of MI [18].
Thus, one explanation is that the anti-arrhythmic effect of EPA treat-
ment early after PCI could contribute to the better prognosis at 1 year
after ACS that was noted in this study. Another possibility is the anti-
inﬂammatory effect of EPA. Pietila et al. reported that high serum CRP
concentrations in acute MI patients treated with thrombolytic drugs
predicted increased mortality up to 6 months [23]. Omega-3 PUFAs at-
tenuates the inﬂammatory response through multiple mechanisms.
Omega-3 PUFAs reduce the content of AA in membrane phospholipids,
resulting in a competitive decrease in the production of AA-derived pro-
inﬂammatory mediators [24]. In addition, the conversion of omega-3
PUFAs into oxygenated bioactive derivatives such as resolvins
and protectins reduces inﬂammation [11–14]. Also, the combination
of EPA and aspirin may enhance the production of resolvins.
For the generation of resolvin E1, aspirin acetylates cyclooxygenase-2
(COX2) in vascular endothelial cells and generates 18R-
hydroperoxyeicosapentaenoic acid (18R-HPEPE), which is further con-
verted via 5-lipoxygenase and additional enzymatic reactions in
Fig. 3. Serum levels of LDL-C (A) and triglyceride (B), and plasma levels of EPA (C) and EPA/AA (D). Values are themean; error bars represent the 95%CI. Solid and broken lines indicate the
EPA group and the control group, respectively.
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inﬂammatory effects of EPA in the early phase after ACS may be beneﬁ-
cial for long-term outcomes.Fig. 4.Kaplan–Meier estimates of the incidence of a primary composite end point by 1 year
(A) and a secondary composite endpoint of either a primary end point or hospitalization
for heart failure (B).Several experimental studies have shown the anti-atherosclerotic
effects of EPA [26,27]. Oral EPA supplementation reduces atheroscle-
rotic lesions in ApoE-deﬁcient mice [26] by inhibiting endothelial acti-
vation. This result was further supported by experimental results
showing that oral EPA administration over a 3-month period inhibited
monocyte adhesion to endothelial cells in vitro and decreased plasma
concentrations of soluble intercellular adhesion molecule 1 [28]. In a
clinical study, EPA treatment decreased carotid intima-media thicknessTable 2
Occurrence of primary and secondary outcome events.
Event Control
(n = 119)
EPA
(n = 119)
HR (95% CI)
Primary outcome
Death from cardiovascular causes 5 (4)a 1 (1) 0.22
(0.47–0.99)
Sudden death 2 (2) 0 (0)
MI 0 (0) 0 (0)
Heart failure 3 (3) 1 (1)
Stroke 0 (0) 0 (0)
Nonfatal MI 0 (0) 1 (1) N/Ab
Nonfatal stroke 4 (3) 0 (0) 0.01
(0.00–45.2)
Coronary revascularization 15 (13) 9 (8) 0.56
(0.24–1.27)
PCI 14 (12) 8 (7)
CABG 1 (1) 1 (1)
Total 24 (20) 11 (9) 0.42
(0.21–0.87)
Secondary outcome
Hospitalization for heart failure 4 (3) 3 (3) 0.72
(0.16–3.24)
Total (primary outcome and
hospitalization for heart failure)
28 (24) 14 (12) 0.48
(0.25–0.82)
Abbreviations: CABG, coronary artery bypass graft; CI, conﬁdence interval; EPA,
eicosapentaenoic acid; HR, hazard ratio; MI, myocardial infarction; PCI, percutaneous cor-
onary intervention.
a Values are expressed as the number of patients followed by the percentage (in pa-
rentheses). HRs and 95% CIs are based on Cox proportional hazard analysis.
b The number of events were too small to evaluate hazard ratio.
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that in patients undergoing PCI for ACS, treatment with EPA plus
rosuvastatin for 9months produced a large increase inﬁbrous cap thick-
ness as determined with optical coherence tomography [30]. Thus, EPA
treatment prevents or stabilizes coronary atherosclerotic plaques,
which reduces the risk of acute plaque rupture and ACS.
Residual cardiovascular risks remain in many patients despite statin
therapy, even at high doses. The residual risks include high levels of tri-
glyceride, very-low-density lipoprotein, and remnant-like lipoparticle
cholesterol (RLP-C). Omega-3 PUFAs have beneﬁcial effects through
the reduction in the levels of these triglyceride-rich lipoproteins
[31–33], suggesting the potential of omega-3 PUFAs as an add-on ther-
apy to statins. In addition, The 2013 ACC/AHA guideline on the treat-
ment of blood cholesterol to reduce atherosclerotic cardiovascular risk
in adults [34] questioned add-on therapy to statins. A recent study
showed that combinatorial statin therapy after ACS reduced cardiovas-
cular outcomes and suggested lowering LDL-C to levels below previous
targets [35]. Thus, the concept that lower LDL-C is beneﬁcial is still im-
portant. In this respect, omega-3 PUFAs containing DHA may raise
LDL-C [36,37]. Highly puriﬁed EPA reduces atherogenic triglyceride-
rich lipoproteins but does not raise LDL-C [30]. Our study supports the
proposition that supplementationwith pure EPAmay reduce cardiovas-
cular events in statin-treated patients.
5. Limitations
There are some limitations in the present study. First, this is a single-
center trial and the number of patients was relatively small, although
the ﬁnal number in the study population did reach the predetermined
target. Second, this study was not of a double-blind design. Although
the investigator in charge of data collection and diagnosis was blind to
treatment allocation, patients and physicians were not. Third, as clinical
outcomes were followed only up to 1 year, it remains unknown
whether this timing of initiation and dose of EPA is optimal to long-
term prognosis in patients after ACS. To establish the clinical utility of
EPA treatment in patients with ACS, a multicenter randomized trial
with a larger population is warranted.
6. Conclusion
Early initiation of EPA combined with statin treatment started
within 24 h after successful primary PCI resulted in reduced cardiovas-
cular events; thus, EPA treatment constitutes a promising therapy after
primary PCI in patients with ACS.
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